AUTL

Peers: ALLO LEGN CABA KYTX GILD FATE CRBU NVS SANA NKTX

| Held by: IBB CANC MOON GWX QQQS APIE IBBQ BIB

Index	-
Market Cap	409.89M
Enterprise Value	574.57M
Income	-279.49M
Sales	117.26M
Book/sh	0.21
Cash/sh	0.76
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	752
IPO	Jun 22, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	3.50
P/B	7.31
P/C	2.02
P/FCF	-
EV/EBITDA	-
EV/Sales	4.90
Quick Ratio	4.36
Current Ratio	4.85
Debt/Eq	4.91
LT Debt/Eq	4.66
Option/Short	Yes / Yes

EPS (ttm)	-1.05
EPS next Y	-0.63
EPS next Q	-0.16
EPS this Y	27.47%
EPS next Y	19.49%
EPS next 5Y	25.87%
EPS past 3/5Y	11.57% 17.04%
Sales past 3/5Y	130.25% 215.43%
EPS Y/Y TTM	-21.91%
Sales Y/Y TTM	287.93%
EPS Q/Q	19.25%
Sales Q/Q	116.09%
Earnings	Nov 10 BMO
EPS/Sales Surpr.	22.80% 18.49%

Insider Own	9.63%
Insider Trans	-0.03%
Inst Own	45.87%
Inst Trans	-2.32%
ROA	-46.04%
ROE	-132.68%
ROIC	-65.92%
Gross Margin	12.87%
Oper. Margin	-210.52%
Profit Margin	-238.34%
SMA20	-6.35%
SMA50	-18.50%
SMA200	-7.60%
Trades

Shs Outstand	266.16M
Shs Float	240.53M
Short Float	3.77%
Short Ratio	4.02
Short Interest	9.07M
52W High	2.58 -40.31%
52W Low	1.17 31.06%
Volatility	5.41% 5.71%
ATR (14)	0.09
RSI (14)	38.43
Beta	2.32
Rel Volume	0.17
Avg Volume	2.26M
Volume	19,106

Perf Week	0.65%
Perf Month	-13.48%
Perf Quarter	-21.03%
Perf Half Y	-1.91%
Perf YTD	-22.61%
Perf Year	-0.65%
Perf 3Y	-54.57%
Perf 5Y	-72.20%
Perf 10Y	-
Recom	1.00
Target Price	8.44
Prev Close	1.52
Price	1.54
Change %	1.32%

Consensus

Strong Buy

Avg. Price Target

$8.44

Implied Upside

+448.1%

Analysts11incl. previous ratings

Rating Distribution10 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Feb 17, 2026	Initiated	HH.C. Wainwright	Buy	$9	+484.4%
Nov 18, 2024	Upgrade	GGoldman	Neutral → Buy	$7 → $7.60	+393.5%
Nov 15, 2024	Upgrade	RRedburn Atlantic	Neutral → Buy	$13	+744.2%
Nov 09, 2023	Initiated	DDeutsche Bank	Buy	$10	+549.4%
Mar 27, 2023	Resumed	WWells Fargo	Overweight	$8	+419.5%
Mar 17, 2023	Initiated	BBryan Garnier	Buy	$5	+224.7%
Jun 14, 2021	Upgrade	JJefferies	Hold → Buy	$6 → $12	+679.2%
Jan 29, 2021	Downgrade	JJP Morgan	Overweight → Neutral	$9	+484.4%
Dec 28, 2020	Resumed	HH.C. Wainwright	Buy	$19	+1,133.8%
Jul 31, 2020	Initiated	JJP Morgan	Overweight
Jul 22, 2020	Initiated	SSunTrust	Buy	$38	+2,367.5%
Apr 22, 2020	Initiated	MMizuho	Buy	$18	+1,068.8%
Sep 23, 2019	Initiated	NNeedham	Buy	$26	+1,588.3%
May 17, 2019	Reiterated	HH.C. Wainwright	Buy	$45 → $41	+2,562.3%
Oct 24, 2018	Initiated	HH.C. Wainwright	Buy	$45	+2,822.1%

Oct-26-26 04:15PM	Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026 (GlobeNewswire)
Oct-05-26 08:30AM	Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026 (GlobeNewswire)
Sep-09-26 07:00AM	Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis (GlobeNewswire)
Aug-11-26 10:24AM	Autolus shares rise as Q2 beat and higher AUCATZYL guidance signal launch momentum (InvestorsHub) +12.56%
07:00AM	Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
04:05PM	Loading…
Aug-03-26 04:05PM	Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026 (GlobeNewswire) +22.15% +7.14%
07:13AM	Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors (GlobeNewswire)
Jul-01-26 04:05PM	Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-30-26 04:10PM	Imviva Biotech Granted FDA IDE Authorization for Cancer Treatment Trial (Exec Edge)
Jun-25-26 07:00AM	Autolus Therapeutics to Participate in Upcoming Investor Conference (GlobeNewswire)
Jun-12-26 04:00AM	Autolus Therapeutics Receives Prix Galien UK Award (GlobeNewswire)
May-27-26 07:00AM	Autolus Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-21-26 05:10PM	Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026 (GlobeNewswire)
May-14-26 07:02PM	Autolus Therapeutics PLC (AUTL) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com) -7.02%
07:00AM	Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
07:00AM	Loading…
May-05-26 07:00AM	Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026 (GlobeNewswire)
Apr-29-26 04:05PM	Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction (GlobeNewswire)
Apr-21-26 04:10PM	Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-07-26 07:00AM	Autolus Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-27-26 07:00AM	Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates (GlobeNewswire) -6.20%
Mar-16-26 04:10PM	Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026 (GlobeNewswire)
Mar-05-26 02:32AM	Autolus Therapeutics Touts $75M Year-1 Obe-cel Launch, Sees $120M-$135M Revenue in 2026 (MarketBeat) -8.90%
Feb-24-26 07:00AM	Autolus Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.20%
Feb-04-26 08:57AM	Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-30-26 06:08AM	New Strong Sell Stocks for January 30th (Zacks)
Jan-22-26 06:01AM	New Strong Sell Stocks for January 22nd (Zacks)
Jan-12-26 07:00AM	Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026 (GlobeNewswire) -17.13%
Jan-06-26 09:00AM	Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL (obe-cel) on the Cellares Cell ShuttleTM Platform (Business Wire) +7.53%
09:00AM	Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL (obe-cel) on the Cellares Cell Shuttle Platform (GlobeNewswire)
Dec-30-25 08:05AM	Needham ups Autolus target, names top pick for 2026 (TipRanks) +5.35%
07:43AM	Loading…
Dec-27-25 07:43AM	Is Autolus Therapeutics plc (AUTL) The Best Get Rich Fast Stocks to Buy Right Now? (Insider Monkey)
Dec-19-25 07:44AM	Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 (PR Newswire)
Dec-08-25 04:05PM	Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025 (GlobeNewswire) -6.29%
08:35AM	Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025 (GlobeNewswire)
Dec-01-25 07:00AM	Autolus Therapeutics Appoints Ryan Richardson to Board of Directors (GlobeNewswire)
Nov-25-25 04:00AM	NICE Recommends AUCATZYL (obecabtagene autoleucel) as a Treatment Option for Adult Patients (=26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹ (GlobeNewswire) +12.10%
Nov-24-25 09:47AM	Is Autolus Therapeutics PLC (AUTL) One of the Fastest-Growing Penny Stocks to Buy Now? (Insider Monkey)
Nov-13-25 04:05PM	Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London (GlobeNewswire) -5.88% +7.03%
Nov-12-25 04:02PM	Autolus Therapeutics PLC (AUTL) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com) -9.33%
07:00AM	Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Nov-10-25 11:21AM	Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? (Zacks)
Nov-03-25 09:05AM	Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025 (GlobeNewswire)
Oct-30-25 07:00AM	Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025 (GlobeNewswire)
Oct-27-25 07:00AM	Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025 (GlobeNewswire) +7.84%
Oct-20-25 07:00AM	Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis (GlobeNewswire)
Oct-15-25 04:05PM	Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.17%
Sep-16-25 08:05AM	Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025 (GlobeNewswire)
Sep-15-25 08:30AM	Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth (PR Newswire)
Aug-24-25 12:53AM	Needham Keeps Buy Rating on Autolus (AUTL) with a $10 Target (Insider Monkey)
Aug-13-25 07:15AM	Autolus Therapeutics sees cash runway to launch, commercialization of obe-cel (TipRanks) -14.62%
03:07AM	Autolus Therapeutics PLC (AUTL) Q2 2025 Earnings Call Highlights: Strong Product Sales Amid ... (GuruFocus.com)
Aug-12-25 07:00AM	Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire) -12.75%
Aug-11-25 09:28AM	Autolus Therapeutics PLC (AUTL) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com) +6.01%
Jul-31-25 10:00AM	European Commission Approves CAR-T Therapy With Lentiviral Vectors Manufactured by AGC Biologics (Business Wire)
Jul-28-25 12:59PM	Unlocking Oncologys Future: 3 Trending Cancer Biotech Stocks with Strong Buy Ratings (Barchart)
Jul-24-25 07:30AM	Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025 (GlobeNewswire)
Jul-21-25 07:00AM	Autolus Therapeutics' CAR T Therapy AUCATZYL (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) (GlobeNewswire)
Jul-15-25 04:05PM	Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.04%
Jun-24-25 05:34PM	Needham Reiterates a Buy Rating on Autolus Therapeutics (AUTL), Keeps the PT at $10 (Insider Monkey)
12:52PM	Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices (PR Newswire)
Jun-20-25 03:00AM	Syncona Ltd (LSE:SYNC) Full Year 2025 Earnings Call Highlights: Navigating Market Challenges ... (GuruFocus.com)
Jun-12-25 02:00AM	Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress (GlobeNewswire)
May-29-25 04:05PM	Autolus Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.06%
May-23-25 08:30AM	Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) (GlobeNewswire)
May-20-25 01:52PM	Autolus Therapeutics plc (AUTL): Analysts See 697% Upside Potential (Insider Monkey)
May-14-25 09:30AM	Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress (GlobeNewswire)
May-09-25 03:20AM	Autolus Therapeutics PLC (AUTL) Q1 2025 Earnings Call Highlights: Strong US Launch and ... (GuruFocus.com)
May-08-25 07:00AM	Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates (GlobeNewswire) +9.76%
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
12:36PM	Autolus Therapeutics Q1 2025 Earnings Preview (Seeking Alpha)
11:09AM	Autolus Therapeutics PLC (AUTL) Q1 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
Apr-26-25 12:15PM	Autolus Therapeutics confirms license of Aucatzyl issued by U.K. MHRA (TipRanks)
Apr-25-25 12:06PM	Autolus Therapeutics Announces License of AUCATZYL (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients ( 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1) (GlobeNewswire)
Apr-23-25 04:05PM	Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event (GlobeNewswire) -5.63% -7.28%
Apr-22-25 07:00AM	Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 (GlobeNewswire) +11.11%
Apr-16-25 01:00AM	Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition (Business Wire)
Apr-02-25 08:40AM	Autolus Therapeutics price target lowered to $10 from $11 at Truist (TipRanks) +11.35%
07:00AM	Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-25 07:00AM	Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025 (GlobeNewswire) -9.03%
Mar-21-25 12:03PM	What To Expect From Autolus Therapeutics PLC (AUTL) Q4 2024 Earnings (GuruFocus.com)
03:03AM	Autolus Therapeutics PLC (AUTL) Q4 2024 Earnings Call Highlights: Financial Growth Amid Rising Costs (GuruFocus.com)
01:44AM	Q4 2024 Autolus Therapeutics PLC Earnings Call (Thomson Reuters StreetEvents)
Mar-20-25 11:56AM	Autolus plans expansion of AUCATZYL centers in 2025 to cover 90% of U.S. patients (SeekingAlpha) -13.66%
11:55AM	Autolus Therapeutics plc (AUTL) Q4 2024 Earnings Conference Call Transcript (SeekingAlpha)
07:00AM	Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates (GlobeNewswire)
Mar-19-25 06:00PM	Here's the major earnings before the open tomorrow (SeekingAlpha) +8.38%
Mar-06-25 07:00AM	Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025 (GlobeNewswire)
04:49AM	Is Autolus Therapeutics plc (AUTL) the Best UK Growth Stock to Buy Now? (Insider Monkey)
Mar-05-25 07:00AM	Autolus Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +12.57%
Jan-17-25 07:00AM	Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings (GlobeNewswire)
Jan-13-25 07:00AM	Autolus Therapeutics Provides Business Updates and 2025 Overview (GlobeNewswire)
Dec-30-24 02:43PM	Why Autolus Therapeutics (AUTL) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-09-24 07:30PM	Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 (GlobeNewswire)
Dec-05-24 07:12PM	Autolus Therapeutics plc (AUTL): A Bull Case Theory (Insider Monkey)
Dec-02-24 07:00AM	Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine (GlobeNewswire)
Nov-19-24 06:11AM	Autolus Therapeutics upgraded to Buy from Neutral at Goldman Sachs (TipRanks)
Nov-15-24 02:03AM	Syncona Ltd (LSE:SYNC) Half Year 2025 Earnings Call Highlights: Navigating Market Challenges ... (GuruFocus.com)
Nov-13-24 02:09AM	Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
02:03AM	Q3 2024 Autolus Therapeutics PLC Earnings Call (Thomson Reuters StreetEvents)
Nov-12-24 07:00AM	Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates (GlobeNewswire) -5.13%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Piccina Cintia	U.S. CCO & Country Gen Manager	Sep 01 '26	Option Exercise	2.35	20,000	47,000	20,000	Sep 03 04:36 PM
Piccina Cintia	U.S. CCO & Country Gen Manager	Sep 02 '26	Sale	2.34	6,713	15,682	13,287	Sep 03 04:36 PM
Piccina Cintia	Officer	Sep 02 '26	Proposed Sale	2.34	6,713	15,679		Sep 02 03:31 PM

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

CEO & DirectorDr. Christian Martin Itin Ph.D.

MBBSDr. Martin Pule M.D.

Senior VP & CFOMr. Robert F. Dolski

Senior VP & COOMr. Christopher Vann

Senior VP of FinanceMr. Patrick McIlvenny

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Autolus Therapeutics plc ADR

Upgrade your Finviz experience